The Future of ALL Therapy

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 176 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Acute Leukemia with a Focus on WHO Classification. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Acute Leukemia with a Focus on WHO Classification (online CE course)
The Future of ALL Therapy

Many different targeted therapies are in various phases of research, trials and approval. Some examples include:
  • Monoclonal antibodies. These are antibodies which are synthesized to recognize a membrane target expressed by the leukemic cells, thus lessening the side effects often seen with standard chemotherapies. A common target for ALL is the CD22 membrane marker. The monoclonal antibody is conjugated with some type of toxin or enzyme inhibitor, thus delivering it directly to the leukemic cells.
  • Proteosome inhibitors. Proteosomes are the large protein complexes in cells which degrade unneeded or excess proteins. By inhibiting this action, proteins build up in the cell and will eventually kill it.
  • JAK inhibitors. A signaling pathway in cells known as the JAK/STAT pathway is a way that leukemic cells can bypass normal growth and proliferation restrictions. By inhibiting this bypass, the cells will stop proliferating and may go on to mature.